1h Free Analyst Time
The autism spectrum disorder therapeutics market is forecasted to grow by USD 772.65 mn during 2022-2027, accelerating at a CAGR of 7.2% during the forecast period. The report on the autism spectrum disorder therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of ASD, growing number of public-private partnerships, and growing awareness about autism spectrum disorders.
The autism spectrum disorder therapeutics market is segmented as below:
By Distribution Channel
- Retail pharmacy
- Hospital pharmacy
- Online pharmacy
By Type
- Stimulants
- Selective serotonin reuptake inhibitors
- Antipsychotic drugs
- Sleep medications
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the autism spectrum disorder therapeutics market covers the following areas:
- Autism spectrum disorder therapeutics market sizing
- Autism spectrum disorder therapeutics market forecast
- Autism spectrum disorder therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global autism spectrum disorder therapeutics market: AutismSTEP, Bristol Myers Squibb Co., CureMark LLC, F. Hoffmann La Roche Ltd., Fraser, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., Les Laboratoires Servier SAS, Neurim Pharmaceuticals Ltd., Novartis AG, Oryzon Genomics SA, Otsuka Holdings Co. Ltd., PaxMedica Inc., Q BioMed Inc., Scioto Biosciences Inc., Spectrum Pharmaceuticals Inc., Stalicla SA, Travere Therapeutics Inc., Yamo Pharmaceuticals LLC, and Zynerba Pharmaceuticals Inc..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing interest in personalized medicine for treatment of ASD.'
According to the report, one of the major drivers for this market is the increasing prevalence of ASD.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AutismSTEP
- Bristol Myers Squibb Co.
- CureMark LLC
- F. Hoffmann La Roche Ltd.
- Fraser
- Jazz Pharmaceuticals Plc
- Johnson and Johnson Services Inc.
- Les Laboratoires Servier SAS
- Neurim Pharmaceuticals Ltd.
- Novartis AG
- Oryzon Genomics SA
- Otsuka Holdings Co. Ltd.
- PaxMedica Inc.
- Q BioMed Inc.
- Scioto Biosciences Inc.
- Spectrum Pharmaceuticals Inc.
- Stalicla SA
- Travere Therapeutics Inc.
- Yamo Pharmaceuticals LLC
- Zynerba Pharmaceuticals Inc.
